Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2927030 | 0.86 | CYP1A2 (0.41) | CYP1A2KMT2AGAANPC1RAB9A | |
| SCHEMBL2929174 | 0.80 | NPC1 (0.41) | CYP1A2KMT2AGAANPC1RAB9A | |
| SCHEMBL3546416 | 0.80 | KMT2A (0.42) | CYP1A2KMT2AGAANPC1RAB9A | |
| SCHEMBL3542014 | 0.80 | CYP1A2 (0.39) | CYP1A2KMT2AGAANPC1RAB9A | |
| SCHEMBL2928372 | 0.79 | NPC1 (0.43) | CYP1A2KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL3551607 | 0.78 | PIK3CA (0.44) | CYP1A2KMT2AGAARAB9AKDM4E | |
| SCHEMBL3309074 | 0.78 | CYP1A2 (0.40) | CYP1A2KMT2AGAANPC1RAB9A | |
| SCHEMBL6379433 | 0.78 | NPC1 (0.44) | KMT2AGAANPC1RAB9AKDM4E | |
| SCHEMBL31389863 | 0.77 | ATM (0.43) | CYP1A2KMT2AGAAMAPTMEN1 | |
| SCHEMBL2522852 | 0.77 | PDCD1 (0.43) | CYP1A2KMT2AGAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112204036-B | Macrocyclic fused pyrazoles as MCL-1 inhibitors | 苏州亚盛药业有限公司 | 2022-12-27 | — | — | CN | disclosed |
| US-20220396587-A1 | MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-12-15 | — | — | US | disclosed |
| WO-2020151738-A1 | MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2020-07-30 | — | — | WO | disclosed |
| US-7812014-B2 | Bicyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH LLC (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812014-B2 | Bicyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH LLC (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812014-B2 | Bicyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH LLC (US) | 2010-10-12 | — | — | US | disclosed |
| EP-1499620-B1 | PROCESS FOR PREPARING 6-ALKYLIDENE PENEM DERIVATIVES | WYETH CORP (US) | 2010-01-27 | — | — | EP | disclosed |
| US-20080312203-A1 | Bicyclic 6-Alkylidene-Penems as Beta-Lactamase Inhibitors | WYETH (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080312203-A1 | Bicyclic 6-Alkylidene-Penems as Beta-Lactamase Inhibitors | WYETH (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080312203-A1 | Bicyclic 6-Alkylidene-Penems as Beta-Lactamase Inhibitors | WYETH (US) | 2008-12-18 | — | — | US | disclosed |
| US-20060276445-A1 | Bicyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| US-20060217361-A1 | Bicyclic 6-alkylidene-penems as beta-lactamase inhibitors | WYETH (US) | 2006-09-28 | — | — | US | disclosed |
| US-7112582-B2 | Bicyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH (US) | 2006-09-26 | — | — | US | disclosed |
| EP-1499620-A1 | PROCESS FOR PREPARING 6-ALKYLIDENE PENEM DERIVATIVES | Wyeth (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1499621-A1 | BICYCLIC 6-ALKYLIDENE-PENEMS AS BETA-LACTAMASES INHIBITORS | Wyeth (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040132708-A1 | Process for preparing 6-alkylidene penem derivatives | WYETH | 2004-07-08 | — | — | US | disclosed |
| US-20040077622-A1 | Bicyclic 5-alkylidene-penems as beta lactamases inhibitors | WYETH | 2004-04-22 | — | — | US | disclosed |
| US-20040053913-A1 | Process for preparing 6-alkylidene penem derivatives | WYETH | 2004-03-18 | — | — | US | disclosed |
| WO-2003093277-A1 | PROCESS FOR PREPARING 6-ALKYLIDENE PENEM DERIVATIVES | WYETH (US) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003093279-A1 | BICYCLIC 6-ALKYLIDENE-PENEMS AS ß-LACTAMASES INHIBITORS | WYETH (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132708-A1 | Process for preparing 6-alkylidene penem derivatives | PGM2, BPGM, MRPL21 | CYP1A2 144/4885KMT2A 3127/4885GAA 549/4885 |
| US-20060276445-A1 | Bicyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors | PEPD, MGAM, PGLS | CYP1A2 699/4885KMT2A 803/4885GAA 53/4885 |
| US-20220396587-A1 | MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS | MCL1, BCL2A1, BCL2L1 | CYP1A2 1662/4885KMT2A 1446/4885GAA 3129/4885 |
| US-20060217361-A1 | Bicyclic 6-alkylidene-penems as beta-lactamase inhibitors | PGLS, BPGM, B2M | CYP1A2 156/4885KMT2A 1229/4885GAA 13/4885 |
| US-20040053913-A1 | Process for preparing 6-alkylidene penem derivatives | PGM2, BPGM, MRPL21 | CYP1A2 144/4885KMT2A 3127/4885GAA 549/4885 |
| US-20040077622-A1 | Bicyclic 5-alkylidene-penems as beta lactamases inhibitors | PGLS, BPGM, B2M | CYP1A2 106/4885KMT2A 1332/4885GAA 12/4885 |
| US-20080312203-A1 | Bicyclic 6-Alkylidene-Penems as Beta-Lactamase Inhibitors | PGLS, PEPD, B2M | CYP1A2 145/4885KMT2A 878/4885GAA 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.